Search
                    Maryland Paid Clinical Trials
A listing of 2668  clinical trials  in Maryland  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            13 - 24 of 2668
        
                Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: University of Maryland, Baltimore, Maryland         
        
        
            Conditions: Carcinoma, Non-Small-Cell Lung
        
            
        
    
                
                                    Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
                                
            
            
        Recruiting
                            
            
                Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatment (relapse) in almost all people; MM may also not respond to initial treatment (refractory). Many people with relapsed refractory MM (RRMM) also have changes in their KRAS and NRAS genes. Researchers want to try a new drug treatment that targets cancer with these changed genes.
Objective:
To test 2 drugs (mirdametinib and sirolimus) in people with RRMM.
Eligibility:
People...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 120 years
            Trial Updated:
                08/22/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
        
            
        
    
                
                                    The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
                                
            
            
        Recruiting
                            
            
                This study is open to adults with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Johns Hopkins University, Baltimore, Maryland         
        
        
            Conditions: Bronchiectasis
        
            
        
    
                
                                    FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
                                
            
            
        Recruiting
                            
            
                Background:
Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface. Researchers want to try a new kind of treatment for RMS: They will collect a person s own T cells, a type of immune cell; then they will change the T cells so they are better able to target the FGFR4 protein and attack RMS tumor cells. The modified T cells are chimeric antigen receptor (CAR) T cells. The treatm...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 3 years and 39 years
            Trial Updated:
                08/22/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Rhabdomyosarcoma
        
            
        
    
                
                                    Environment and Alcohol: A Pilot Study
                                
            
            
        Recruiting
                            
            
                Background:
Alcohol use disorder (AUD) is a chronic disease that causes more than 140,000 US deaths each year. AUD treatment often includes therapy and medication. Some people with AUD may also benefit from behavioral and lifestyle changes.
Objective:
To evaluate the effects of different activities and environments on drinking behaviors and mental health in people with AUD.
Eligibility:
People aged 21 years and older with AUD.
Design:
Participants will have up to 10 study visits in Baltim...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 21 years and 100 years
            Trial Updated:
                08/22/2025
            
            Locations: National Institute on Drug Abuse, Baltimore, Maryland         
        
        
            Conditions: Alcohol Use Disorder
        
            
        
    
                
                                    Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
                                
            
            
        Recruiting
                            
            
                Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Investigative Site US111, Baltimore, Maryland         
        
        
            Conditions: Hidradenitis Suppurativa (HS)
        
            
        
    
                
                                    Childhood-Onset Essential Hypertension Natural History Study
                                
            
            
        Recruiting
                            
            
                Background:
Childhood-onset essential hypertension (COEH) is high blood pressure that develops in children and teens. High blood pressure is a major risk factor for heart disease. COEH is more likely to be caused by changes in genes rather than by factors like stress or diet. Researchers want to learn more about how changes in genes relate to COEH. They hope to use that information to develop better treatments for children with high blood pressure.
Objective:
This natural history study will l...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 99 years
            Trial Updated:
                08/22/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Hypertension, Essential Hypertension
        
            
        
    
                
                                    A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.             
        
        
    Gender:
                MALE
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Local Institution - 0054, Baltimore, Maryland         
        
        
            Conditions: Metastatic Castration-resistant Prostate Cancer
        
            
        
    
                
                                    A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                08/22/2025
            
            Locations: Research Site, Baltimore, Maryland         
        
        
            Conditions: Staphylococcus Aureus
        
            
        
    
                
                                    Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
                                
            
            
        Recruiting
                            
            
                Background:
Fanconi anemia (FA) is a rare, inherited cancer syndrome. FA causes a range of physical issues. Children with FA may have abnormal features; these may include a small head and eyes and issues with their internal organs. Young adults have a much higher risk of cancer. To screen for these cancers, people with FA may need to pursue many visits with different doctors. This constant need for cancer screening may cause anxiety for people with FA.
Objective:
To learn more about anxiety r...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                08/22/2025
            
            Locations: National Cancer Institute (NCI), Bethesda, Maryland         
        
        
            Conditions: Fanconi Anemia
        
            
        
    
                
                                    A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
                                
            
            
        Recruiting
                            
            
                PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptom...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Flourish- Bowie, Bowie, Maryland         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    Predicting Future Errors During Skill Performance
                                
            
            
        Recruiting
                            
            
                Background:
Many tasks people do every day require a series of individual movements. Control over these movements is called motor skills. But even highly skilled people can make mistakes. Researchers have found that they can predict when a person will make a mistake 0.1 second before it happens. Now, they want to find out if they can increase that time up to 1 second-long enough to warn the person and prevent the mistake.
Objective:
To see if motor skill errors can be detected up to 1 second...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 35 years
            Trial Updated:
                08/22/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Healthy
        
            
        
    